MaxCyte, Inc. (LON:MXCT - Get Free Report)'s share price hit a new 52-week low on Tuesday . The company traded as low as GBX 177 ($2.35) and last traded at GBX 202.77 ($2.69), with a volume of 418041 shares. The stock had previously closed at GBX 192 ($2.55).
MaxCyte Trading Down 1.0 %
The firm has a market capitalization of £254.77 million, a P/E ratio of -7.07 and a beta of 1.13. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The company's fifty day moving average is GBX 249.48 and its 200-day moving average is GBX 292.54.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
